Iambic Therapeutics' (NASDAQ:IAM - Get Free Report) quiet period will expire on Tuesday, November 24th. Iambic Therapeutics had issued 9,375,000 shares in its public offering on October 15th. The total size of the offering was $150,000,000 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Analyst Ratings Changes
Several brokerages have recently weighed in on IAM. Zacks Research began coverage on shares of Iambic Therapeutics in a report on Tuesday, November 10th. They issued a "hold" rating on the stock. JPMorgan Chase & Co. started coverage on shares of Iambic Therapeutics in a report on Monday, November 9th. They set an "overweight" rating and a $22.00 price target for the company. Jefferies Financial Group assumed coverage on shares of Iambic Therapeutics in a research report on Tuesday, November 10th. They issued a "buy" rating and a $35.00 price objective for the company. Citigroup began coverage on shares of Iambic Therapeutics in a research report on Monday, November 9th. They issued a "buy" rating and a $22.00 price objective for the company. Finally, Wall Street Zen raised Iambic Therapeutics to a "hold" rating in a report on Saturday, November 7th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $27.25.
Read Our Latest Stock Report on IAM
Iambic Therapeutics Stock Down 9.5%
Iambic Therapeutics stock opened at $11.85 on Tuesday. Iambic Therapeutics has a 1-year low of $9.60 and a 1-year high of $25.00.
Iambic Therapeutics (NASDAQ:IAM - Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($6.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($5.90). On average, equities research analysts predict that Iambic Therapeutics will post -1.83 earnings per share for the current year.
Insider Activity at Iambic Therapeutics
In related news, Director Evan Lockwood Rachlin purchased 718,750 shares of the stock in a transaction dated Friday, October 16th. The shares were acquired at an average cost of $16.00 per share, with a total value of $11,500,000.00. Following the purchase, the director directly owned 2,588,248 shares in the company, valued at $41,411,968. This trade represents a 38.45% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.
About Iambic Therapeutics
(
Get Free Report)
Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company's pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic's broader work focuses on advancing drug candidates generated through its technology platform.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Iambic Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iambic Therapeutics wasn't on the list.
While Iambic Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.